Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291785
Status:
COMPLETED
Last Update Posted:
2011-06-08
First Post:
2006-02-14
Brief Title:
Phase III CT 2106 and 5-FUFA in Colorectal Cancer
Sponsor:
CTI BioPharma
Organization:
CTI BioPharma
Study Overview
Official Title:
Phase III Study of CT-2106 in Combination With Infusional 5-fluorouracilFolinic Acid 5-FUFAde Gramont Schedule as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FUFA Regimen
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CT-2106 a camptothecin CPT conjugate is a new generation of topoisomerase I inhibitors designed to deliver higher more effective chemotherapy to tumor tissue with less toxicity to normal tissues The objective of this study is to determine the dose limiting toxicities safety profile and antitumor activity of CT-2016 in combination with 5-FU and folic acid for the treatment of colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None